key: cord-0713586-tz7njnma authors: Mina, Michael J; Peto, Tim E; García-Fiñana, Marta; Semple, Malcolm G; Buchan, Iain E title: Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19 date: 2021-02-17 journal: Lancet DOI: 10.1016/s0140-6736(21)00425-6 sha: beec2460bab32cff746143003d85511f2ff63a5f doc_id: 713586 cord_uid: tz7njnma nan individuals test positive and isolate for 10 days. In our view, current PCR testing is therefore not the appropriate gold standard for evaluating a SARS-CoV-2 public health test. Most people infected with SARS-CoV-2 are contagious for 4-8 days. 7 Specimens are generally not found to contain culture-positive (potentially contagious) virus beyond day 9 after the onset of symptoms, with most transmission occurring before day 5. 7, 8 This timing fits with the observed patterns of virus transmission (usually 2 days before to 5 days after symptom onset), which led public health agencies to recommend a 10-day isolation period. 9 The short window of transmissibility contrasts with a median 22-33 days of PCR positivity (longer with severe infections and somewhat shorter among asymptomatic individuals). 10 This suggests that 50-75% of the time an individual is PCR positive, they are likely to be post-infectious. 11, 12 Once SARS-CoV-2 replication has been controlled by the immune system, RNA levels detectable by PCR on respiratory secretions fall to very low levels when individuals are much less likely to infect others. [13] [14] [15] The remaining RNA copies can take weeks, or occasionally months, 16, 17 to clear, during which time PCR remains positive. 7 A public health test for detecting someone who might be contagious is, by logical deduction, expected to have a sensitivity of around 30-40% versus PCR when testing a random sample of asymptomatic people in a steady-state outbreak. 18 Furthermore, the asymmetry of RNA reflecting more infectiousness nearer to the time of exposure, means that the sensitivity of the ideal test of infectiousness when measured against PCR may vary across the epidemic curve, from as high as 50-60% when an outbreak is surging to 20-30% or less as infections decline. 19 LFT and the UK testing programme have been criticised 1-3,5 for poor sensitivity in people without symptoms. In our view, these criticisms misinterpreted data from the interim report on the pilot of community testing in Liverpool, UK. 20, 21 When paired LFT and PCR testing was done in Liverpool, the epidemic curve was declining. 20 At this point, a priori one should expect a public health test that is highly sensitive for detecting infectious virus to show low overall sensitivity relative to PCR in people without symptoms or known exposures. Further confusion reigns over PCR cycle threshold (Ct) values, viral loads, and infectiousness. In the Liverpool pilot, Innova LFT picked up 19 of 24 (79%) samples with Ct below 20 and ten of 11 (91%) samples with Ct below 18. 20 The 66% sensitivity in the Liverpool interim report 20 was based cautiously on Ct below or equal to 25 indicating viable virus. For the laboratory processing of the Liverpool samples, Ct values of 21-18 most likely reflect the 100 000 to 1 million RNA copies per mL, quantities below which virus cultures usually become negative and transmission risks are low. [22] [23] [24] Other laboratories place this threshold at a Ct of 30. 24 There is no international standardisation between laboratories and assays, leaving Ct calibra tion with viral load poorly reported and easy to misunderstand. Early findings, widely reported, 3 from a study by Ferguson and colleagues, 25 suggested that LFT had only 3% sensitivity for detecting SARS-CoV-2 among PCR-positive students at Birmingham University. Test underperformance was implied to explain finding only two positive results among 7189 individuals tested with Innova LFT. 25 In that study, 25 in a random sample of 710 (10%) LFT-negative individuals there were six PCR-positive results. That finding was extrapolated to 60 cases in the whole cohort, giving an extrapolated sensitivity of two of 62 (3·2%). The Ct values from the six PCR-positive samples were projected to Ct values for the 60 cases (54 unobserved plus six observed); in all six observed cases, viral loads were very low (Ct ≥29 reflecting around <1000 RNA copies per mL in the laboratory used)-when LFT should be negative. By comparison, the Liverpool pilot saw virus levels 1000 to 1 million times higher. 20 In our view, the Birmingham study showed that PCR-positive asymptomatic students at a time of falling COVID-19 incidence had low viral loads compared with symptomatic members of the public attending testing centres and that LFT was working as expected. 26 We wholeheartedly support healthy scientific debate to inform policies promptly. The COVID-19 road ahead looks challenging; therefore, we need big, bold actions across science and society, such as the Liverpool community testing pilot. The prompt evidence from such pilots can inform policies and help maintain public confidence in the public health responses needed to navigate this pandemic's onward path. IEB, MG-F, and MGS received grant funding from the UK Department of Health and Social Care to evaluate LFT in the Liverpool pilot that is discussed in this Comment. IEB reports fees from AstraZeneca as chief data scientist adviser via Liverpool University and a senior investigator grant from the National Institute The COVID-19 pandemic and response are having profound impacts on India's people, leading to myriad health-care challenges, a looming economic recession, and humanitarian crises. 1 The long-standing need for universal health coverage (UHC) in India has been brought into sharp focus by the pandemic. The mission of the Lancet Citizens' Commission on reimagining India's health system is to lay out the path to achieving UHC in India in the coming decade. A guiding principle for this Commission is that structural change towards UHC can only be attained through consultative and participatory engagement Reimagining India's health system: a Lancet Citizens' Commission for Health Research (NIHR) outside the submitted work. MGS is Chair of the Infectious Disease Scientific Advisory Board and a minority shareholder in Integrum Scientific LLC, Greensboro, NC, USA, a company that has interests in COVID-19 testing but not with lateral flow technology, and reports grants from the NIHR, the Medical Research Council, and the Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool. MJM reports research funding by the US National Institutes of Health Director's Early Independence Award DP5-OD028145 and from Open Philanthropy and Good Ventures. TEP is supported by the NIHR Health Protection Research Unit in test roll out Lateral flow tests cannot rule out SARS-CoV-2 infection Covid-19: tests on students are highly inaccurate, early findings show Covid-19: Controversial rapid test policy divides doctors and scientists Covid-19: controversial rapid test policy divides doctors and scientists Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis Viral cultures for COVID-19 infectious potential assessment-a systematic review Criteria for releasing COVID-19 patients from isolation: scientific brief Prolonged persistence of SARS-CoV-2 RNA in body fluids Predicting infectious SARS-CoV-2 from diagnostic samples Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19 Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19 Virological assessment of hospitalized patients with COVID-2019 SARS-CoV-2 transmission dynamics should inform policy Virology, transmission, and pathogenesis of SARS-CoV-2 Using viral load and epidemic dynamics to optimize 2 pooled testing in resource constrained settings Estimating epidemiologic dynamics from single cross-sectional viral load distributions Liverpool Covid-19 Community Testing Pilot interim report Response to: Deeks et al. Briefing note for journalists on harm from continued rollout of the Innova Lateral Flow Test An observational study of SARS-CoV-2 infectivity by viral load and 2 demographic factors and the utility lateral flow devices to prevent 3 transmission Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses-Wisconsin Validation testing to determine the effectiveness of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings Put to the test: use of rapid testing technologies for covid-19